Quantum-computing company IonQ has entered into a strategic collaboration with CCRM, a global leader in regenerative medicine and advanced therapies to accelerate the development of next-generation therapeutics using hybrid quantum and quantum-AI technologies.
Under the partnership, IonQ becomes the core quantum-technology partner across CCRM’s worldwide network of advanced-therapy hubs. The companies have committed investment capital and intend to jointly build quantum-biotech initiatives.
The first projects under this collaboration will begin in 2026 in Canada and Sweden, targeting areas such as bioprocess optimisation, disease-modelling workflows, and quantum-enhanced simulation to support the design and manufacturing of advanced therapies.
By combining CCRM’s extensive infrastructure — including GMP-compliant manufacturing facilities and a large global network of academic and industry partners with IonQ’s quantum-computing capabilities, the collaboration aims to overcome some of the most complex challenges in biomanufacturing and scale up regenerative medicine efforts.
This move reflects a growing trend of applying cutting-edge quantum technologies to life sciences, potentially paving the way for faster development of advanced therapies, improved manufacturing processes, and more scalable delivery of treatments.
Also Read